海洋由来医薬品市場：供給源、薬剤タイプ、エンドユーザー別-2025～2030年の世界予測

海洋由来医薬品市場は、2023年に41億米ドルと評価され、2024年には44億4,000万米ドルに達すると予測され、CAGR 8.70％で成長し、2030年には73億6,000万米ドルに達すると予測されています。

海洋由来医薬品とは、藻類、細菌、菌類、海綿動物、軟体動物などの海洋生物から抽出または合成される医薬品を指します。これらの医薬品は、がん、感染症、心血管疾患、炎症の治療など、幅広い治療用途を包含しています。海洋由来の医薬品が必要とされる背景には、そのユニークな生物活性化合物があり、陸上生物にはない新しい作用機序を持つことが多いです。これらの医薬品は、病院、研究機関、製薬メーカーなどを最終用途として、製薬とバイオテクノロジーの両方の場面で応用されています。

海洋由来医薬品市場は、海洋バイオテクノロジーの技術進歩、海洋生物多様性研究への資金提供の増加、新規治療に対する需要の急増といった要因の影響を受けています。慢性疾患の罹患率の上昇と海洋生物製品の利点に対する意識の高まりが、市場の成長をさらに後押ししています。最近のビジネス機会は、未開の海洋生息地の綿密な調査、学界と産産業の協力関係の促進、サステイナブル採取技術の開発などにあります。しかし課題としては、厳しい規制の枠組み、研究開発コストの高さ、環境保全の取り組みに関する不確実性などがあります。規制機関には、プロセスを合理化し、サステイナブル実践を促進することで、環境保全の取り組みと医薬品開発を一致させることが求められています。

未発見の海洋生物のバイオプロスペクティング、ドラッグデリバリーシステムの改良、海洋から着想を得た類似物質の合成などのセグメントでは、イノベーションの機会があふれています。ゲノミクスやメタボロミクスに焦点を当てた洞察に満ちた調査により、複雑な海洋生物システムを解明し、画期的な新薬発見の可能性を高めることができます。市場の性質は非常にダイナミックであり、科学的探究と商業的実行可能性の組み合わせによって動かされます。このセグメントでの成長を目指す企業は、学際的な研究に投資し、データ分析に人工知能を活用し、世界の共同研究を行うことで、限界を克服し、このセグメントで必要とされる専門知識を最大限に活用する必要があります。

市場力学：急速に進化する海洋由来医薬品市場の主要市場洞察を公開

海洋由来医薬品市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネス機会の獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の慢性疾患の蔓延
  • 政府と民間当局による海洋バイオテクノロジーへの投資の増加
• 市場抑制要因
  • 海洋資源に関連する新薬の開発コストの高さ
• 市場機会
  • 海洋由来医薬品の抽出・合成技術の進歩の増加
  • 海洋由来医薬品の治療可能性拡大への注目の高まり
• 市場課題
  • 海洋由来医薬品に関する環境と倫理的懸念

ポーターのファイブフォース：海洋由来医薬品市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォースフレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することで、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：海洋由来医薬品市場における外部からの影響の把握

外部マクロ環境要因は、海洋由来医薬品市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：海洋由来医薬品市場における競合情勢の把握

海洋由来医薬品市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス：海洋由来医薬品市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、海洋由来医薬品市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨：海洋由来医薬品市場における成功への道筋を描く

海洋由来医薬品市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネス機会を活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目セグメントを網羅した市場の包括的な分析を提供しています。

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力を評価します。

2.市場の開拓度：新興市場における成長機会を特定し、既存セグメントにおける拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化：最近の製品発売、未開拓の地域、産業の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています。

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、地域はどこか？

3.市場を形成する主要技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で慢性疾患の罹患率が増加
    • 政府と民間による海洋バイオテクノロジーへの投資増加
  • 抑制要因
    • 海洋資源に関連する新薬の開発コストの高さ
  • 機会
    • 海洋由来医薬品の抽出・合成技術の進歩
    • 海洋由来医薬品の治療可能性拡大への注目が高まる
  • 課題
    • 海洋由来医薬品に関する環境と倫理に関する懸念
• 市場セグメンテーション分析
  • 供給源：スキンケア製品を中心に藻類の使用が増加
  • エンドユーザー：規制当局の承認を得た病院全体で海洋由来医薬品の潜在性が高い
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 海洋由来医薬品市場：供給源別

• イントロダクション
• 藻類
• 無脊椎動物
• 微生物

第7章 海洋由来医薬品市場：薬剤タイプ別

• イントロダクション
• 鎮痛剤
• 抗凝固剤
• 抗炎症
• 抗菌性
• 抗ウィルス薬
• 抗がん剤

第8章 海洋由来医薬品市場：エンドユーザー別

• イントロダクション
• 病院
• 製薬・バイオテクノロジー企業
• 研究・学術機関

第9章 南北アメリカの海洋由来医薬品市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋の海洋由来医薬品市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの海洋由来医薬品市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
  • カリフォルニア大学サンディエゴ校、肺腫瘍へのドラッグデリバリーを強化する藻類ベースのマイクロボット技術を開発
  • GITAM、がんや抗生物質耐性と闘う革新的な海洋医薬品発見センターに136億9,000万インドルピーを確保
• 戦略分析と提言

企業一覧

• Aker BioMarine ASA
• Aphios Corporation
• Eisai Co., Ltd.
• Gimv NV
• GlycoMar Limited
• Marinova Pty Ltd.
• Nereus Pharmaceuticals, Inc.
• Perha Pharmaceuticals
• Pfizer, Inc.
• Pharma Mar, S.A.
• TransAlgae
• Zelnova Zeltia

LIST OF FIGURES

• FIGURE 1. MARINE DERIVED DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. MARINE DERIVED DRUGS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL MARINE DERIVED DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL MARINE DERIVED DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL MARINE DERIVED DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS MARINE DERIVED DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS MARINE DERIVED DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES MARINE DERIVED DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES MARINE DERIVED DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC MARINE DERIVED DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC MARINE DERIVED DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA MARINE DERIVED DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA MARINE DERIVED DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. MARINE DERIVED DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. MARINE DERIVED DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. MARINE DERIVED DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL MARINE DERIVED DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL MARINE DERIVED DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL MARINE DERIVED DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. MARINE DERIVED DRUGS MARKET DYNAMICS
• TABLE 7. GLOBAL MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL MARINE DERIVED DRUGS MARKET SIZE, BY ALGAE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL MARINE DERIVED DRUGS MARKET SIZE, BY INVERTEBRATES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL MARINE DERIVED DRUGS MARKET SIZE, BY MICROORGANISMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL MARINE DERIVED DRUGS MARKET SIZE, BY ANALGESICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL MARINE DERIVED DRUGS MARKET SIZE, BY ANTI-COAGULANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL MARINE DERIVED DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL MARINE DERIVED DRUGS MARKET SIZE, BY ANTI-MICROBIAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL MARINE DERIVED DRUGS MARKET SIZE, BY ANTI-VIRAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL MARINE DERIVED DRUGS MARKET SIZE, BY ANTICANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL MARINE DERIVED DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL MARINE DERIVED DRUGS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL MARINE DERIVED DRUGS MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS MARINE DERIVED DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 29. BRAZIL MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 30. BRAZIL MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 31. BRAZIL MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 32. CANADA MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 33. CANADA MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 34. CANADA MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 35. MEXICO MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 36. MEXICO MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 37. MEXICO MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 40. UNITED STATES MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 41. UNITED STATES MARINE DERIVED DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 44. ASIA-PACIFIC MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 45. ASIA-PACIFIC MARINE DERIVED DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 46. AUSTRALIA MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 47. AUSTRALIA MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 48. AUSTRALIA MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 49. CHINA MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 50. CHINA MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 51. CHINA MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 52. INDIA MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 53. INDIA MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 54. INDIA MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 55. INDONESIA MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 56. INDONESIA MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 57. INDONESIA MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 58. JAPAN MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 59. JAPAN MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 60. JAPAN MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 61. MALAYSIA MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 62. MALAYSIA MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 63. MALAYSIA MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 64. PHILIPPINES MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 65. PHILIPPINES MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 66. PHILIPPINES MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 67. SINGAPORE MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 68. SINGAPORE MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 69. SINGAPORE MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 70. SOUTH KOREA MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 71. SOUTH KOREA MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 72. SOUTH KOREA MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 73. TAIWAN MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 74. TAIWAN MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 75. TAIWAN MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 76. THAILAND MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 77. THAILAND MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 78. THAILAND MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 79. VIETNAM MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 80. VIETNAM MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 81. VIETNAM MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 84. EUROPE, MIDDLE EAST & AFRICA MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 85. EUROPE, MIDDLE EAST & AFRICA MARINE DERIVED DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 86. DENMARK MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 87. DENMARK MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 88. DENMARK MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 89. EGYPT MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 90. EGYPT MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 91. EGYPT MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 92. FINLAND MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 93. FINLAND MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 94. FINLAND MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 95. FRANCE MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 96. FRANCE MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 97. FRANCE MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 98. GERMANY MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 99. GERMANY MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 100. GERMANY MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 101. ISRAEL MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 102. ISRAEL MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 103. ISRAEL MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 104. ITALY MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 105. ITALY MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 106. ITALY MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 107. NETHERLANDS MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 108. NETHERLANDS MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 109. NETHERLANDS MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 110. NIGERIA MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 111. NIGERIA MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 112. NIGERIA MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 113. NORWAY MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 114. NORWAY MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 115. NORWAY MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 116. POLAND MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 117. POLAND MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 118. POLAND MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 119. QATAR MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 120. QATAR MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 121. QATAR MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 122. RUSSIA MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 123. RUSSIA MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 124. RUSSIA MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 125. SAUDI ARABIA MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 126. SAUDI ARABIA MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 127. SAUDI ARABIA MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH AFRICA MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH AFRICA MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 130. SOUTH AFRICA MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 131. SPAIN MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 132. SPAIN MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 133. SPAIN MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 134. SWEDEN MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 135. SWEDEN MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 136. SWEDEN MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 137. SWITZERLAND MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 138. SWITZERLAND MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 139. SWITZERLAND MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 140. TURKEY MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 141. TURKEY MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 142. TURKEY MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 143. UNITED ARAB EMIRATES MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 144. UNITED ARAB EMIRATES MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 145. UNITED ARAB EMIRATES MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 146. UNITED KINGDOM MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 147. UNITED KINGDOM MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 148. UNITED KINGDOM MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 149. MARINE DERIVED DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 150. MARINE DERIVED DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

The Marine Derived Drugs Market was valued at USD 4.10 billion in 2023, expected to reach USD 4.44 billion in 2024, and is projected to grow at a CAGR of 8.70%, to USD 7.36 billion by 2030.

Marine-derived drugs refer to pharmaceuticals that are extracted or synthesized from marine organisms, such as algae, bacteria, fungi, sponges, and mollusks. The scope of these drugs encompasses a wide range of therapeutic applications, including treatments for cancer, infections, cardiovascular diseases, and inflammation. The necessity for marine-derived drugs is driven by their unique bioactive compounds, which often offer novel mechanisms of action not found in terrestrial organisms. These drugs are applied in both pharmaceutical and biotechnology settings, with end-use scope including hospitals, research institutions, and pharmaceutical manufacturers.

The market for marine-derived drugs is influenced by factors such as technological advancements in marine biotechnology, increased funding for marine biodiversity research, and a surge in demand for novel therapeutics. The rising incidence of chronic diseases and the growing awareness of the benefits of marine bioproducts further bolster market growth. Recent opportunities lie in the in-depth exploration of uncharted marine habitats, fostering collaborations partnerships between academia and industry, and the development of sustainable harvesting techniques. However, challenges include stringent regulatory frameworks, high research and development costs, and uncertainties related to environmental conservation efforts. There's a need for regulatory bodies to streamline processes and promote sustainable practices, aligning conservation efforts with pharmaceutical development.

Innovation opportunities abound in areas such as bioprospecting for undiscovered marine organisms, the improvement of drug delivery systems, and the synthesis of marine-inspired analogs. Insightful research can focus on genomics and metabolomics to unravel complex marine biosystems, advancing the potential for groundbreaking drug discoveries. The nature of the market is highly dynamic, driven by a combination of scientific inquiry and commercial viability. Companies aiming to grow in this space should invest in cross-disciplinary research, leverage artificial intelligence for data analysis, and engage in global collaborations to overcome limitations and maximize the expertise required in the field.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Marine Derived Drugs Market

The Marine Derived Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of chronic diseases worldwide
  • Growing investments in marine biotechnologies by government and private authorities
• Market Restraints
  • High cost of development of new drugs associated with marine sources
• Market Opportunities
  • Increasing advances in extraction and synthesis technologies of marine derived drugs
  • Growing focus on expanding therapeutic potential of marine-derived drugs
• Market Challenges
  • Environmental and ethical concerns with marine derived drugs

Porter's Five Forces: A Strategic Tool for Navigating the Marine Derived Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Marine Derived Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Marine Derived Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Marine Derived Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Marine Derived Drugs Market

A detailed market share analysis in the Marine Derived Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Marine Derived Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Marine Derived Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Marine Derived Drugs Market

A strategic analysis of the Marine Derived Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Marine Derived Drugs Market, highlighting leading vendors and their innovative profiles. These include Aker BioMarine ASA, Aphios Corporation, Eisai Co., Ltd., Gimv NV, GlycoMar Limited, Marinova Pty Ltd., Nereus Pharmaceuticals, Inc., Perha Pharmaceuticals, Pfizer, Inc., Pharma Mar, S.A., TransAlgae, and Zelnova Zeltia.

Market Segmentation & Coverage

This research report categorizes the Marine Derived Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Source, market is studied across Algae, Invertebrates, and Microorganisms.
• Based on Drug Type, market is studied across Analgesics, Anti-coagulants, Anti-inflammatory, Anti-microbial, Anti-viral, and Anticancer.
• Based on End-User, market is studied across Hospitals, Pharmaceutical & Biotechnology Companies, and Research & Academic Institutions.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of chronic diseases worldwide
    • 5.1.1.2. Growing investments in marine biotechnologies by government and private authorities
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of development of new drugs associated with marine sources
  • 5.1.3. Opportunities
    • 5.1.3.1. Increasing advances in extraction and synthesis technologies of marine derived drugs
    • 5.1.3.2. Growing focus on expanding therapeutic potential of marine-derived drugs
  • 5.1.4. Challenges
    • 5.1.4.1. Environmental and ethical concerns with marine derived drugs
• 5.2. Market Segmentation Analysis
  • 5.2.1. Source: Growing usage of algae especially in skincare products
  • 5.2.2. End-User: High potential of marine derived drugs across hospitals that have obtained regulatory approvals
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Marine Derived Drugs Market, by Source

• 6.1. Introduction
• 6.2. Algae
• 6.3. Invertebrates
• 6.4. Microorganisms

7. Marine Derived Drugs Market, by Drug Type

• 7.1. Introduction
• 7.2. Analgesics
• 7.3. Anti-coagulants
• 7.4. Anti-inflammatory
• 7.5. Anti-microbial
• 7.6. Anti-viral
• 7.7. Anticancer

8. Marine Derived Drugs Market, by End-User

• 8.1. Introduction
• 8.2. Hospitals
• 8.3. Pharmaceutical & Biotechnology Companies
• 8.4. Research & Academic Institutions

9. Americas Marine Derived Drugs Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Marine Derived Drugs Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Marine Derived Drugs Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. UC San Diego Innovates Algae-Based Microbot Technology for Enhanced Lung Tumor Drug Delivery
  • 12.3.2. GITAM secures INR 13.69 crore for innovative marine drug discovery center to combat cancer and antibiotic resistance
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Aker BioMarine ASA
• 2. Aphios Corporation
• 3. Eisai Co., Ltd.
• 4. Gimv NV
• 5. GlycoMar Limited
• 6. Marinova Pty Ltd.
• 7. Nereus Pharmaceuticals, Inc.
• 8. Perha Pharmaceuticals
• 9. Pfizer, Inc.
• 10. Pharma Mar, S.A.
• 11. TransAlgae
• 12. Zelnova Zeltia